Provided by Tiger Trade Technology Pte. Ltd.

Travere Therapeutics, Inc.

65.71
+1.251.94%
Pre-market: 65.900.1900+0.29%08:01 EDT
Volume:1.62M
Turnover:106.77M
Market Cap:6.19B
PE:-137.92
High:66.38
Open:64.78
Low:64.50
Close:64.46
52wk High:66.38
52wk Low:17.05
Shares:94.26M
Float Shares:92.77M
Volume Ratio:1.30
T/O Rate:1.75%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.4764
EPS(LYR):-0.2864
ROE:-236.35%
ROA:-3.73%
PB:252.59
PE(LYR):-229.47

Loading ...

Travere Therapeutics, Inc. : H.c. Wainwright Raises Target Price to $57 From $47

THOMSON REUTERS
·
May 05

Travere Therapeutics Inc : Leerink Partners Raises Target Price to $55 From $50

THOMSON REUTERS
·
May 05

Travere Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
May 05

Travere Therapeutics director Roy D. Baynes disposes of USD 431,145 common shares

Reuters
·
May 05

Travere Therapeutics Q1 product sales rise on FILSPARI demand

Reuters
·
May 05

Travere Q1 FY26 net loss narrows to $37.1 million; net product sales climb 64.1% to $124.5 million

Reuters
·
May 05

BRIEF-Travere Therapeutics Q1 EPS USD -0.4

Reuters
·
May 05

Travere Therapeutics Q1 Operating Income USD -36.915 Million

THOMSON REUTERS
·
May 05

Press Release: Travere Therapeutics Reports First Quarter 2026 Financial Results

Dow Jones
·
May 05

Travere Therapeutics Inc expected to post a loss of 26 cents a share - Earnings Preview

Reuters
·
May 02

Travere Therapeutics (TVTX) Gets a Buy from Guggenheim

TIPRANKS
·
Apr 29

Press Release: Travere Therapeutics to Report First Quarter 2026 Financial Results

Dow Jones
·
Apr 28

Travere Therapeutics to report quarterly results, host conference call

Reuters
·
Apr 28

A Look At Travere Therapeutics (TVTX) Valuation After FILSPARI’s Expanded FDA Approval In FSGS

Simply Wall St.
·
Apr 25

Travere Therapeutics Inc : Jefferies Raises Target Price to $50 From $42

THOMSON REUTERS
·
Apr 24

Travere Therapeutics (TVTX) Receives a Buy from Piper Sandler

TIPRANKS
·
Apr 24

A Look At Travere Therapeutics (TVTX) Valuation After FDA Expands FILSPARI Approval For FSGS

Simply Wall St.
·
Apr 18

Travere Therapeutics (TVTX) Gets a Buy from Evercore ISI

TIPRANKS
·
Apr 17

Travere director Gary Lyons disposes of common shares worth $328,560

Reuters
·
Apr 17

Travere director Roy D. Baynes disposes of 32,750 shares worth $1,345,155

Reuters
·
Apr 17